Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461241 | 0.88 | SIGMAR1 (0.53) | SIGMAR1DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL5451785 | 0.86 | POLB (0.52) | SIGMAR1DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL5461247 | 0.81 | SIGMAR1 (0.56) | SIGMAR1DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL5458343 | 0.80 | SIGMAR1 (0.53) | SIGMAR1DRD2DRD3DRD4ABCB1 | |
| SCHEMBL5454057 | 0.79 | ABCB1 (0.54) | SIGMAR1DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL4042171 | 0.76 | SIGMAR1 (0.71) | SIGMAR1DRD2DRD3DRD4ABCB1 | |
| SCHEMBL4043245 | 0.76 | SIGMAR1 (0.71) | SIGMAR1DRD2DRD3DRD4ABCB1 | |
| SCHEMBL5447833 | 0.76 | ALDH1A1 (0.65) | KDM4EALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL7169066 | 0.76 | SIGMAR1 (0.64) | SIGMAR1DRD2DRD3DRD4TMEM97 | |
| SCHEMBL14721849 | 0.75 | DRD3 (0.79) | SIGMAR1DRD2DRD3DRD4TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | SIGMAR1 215/4885DRD2 1065/4885DRD3 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.